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The molecular basis and functional properties of a variant antithrombin (AT) protein. AT Budapnt 3. were studied. A single base substilution 
was identified in codon 99, gC+cC. altering the normal lcucine lo phcnylalaninc. The proband presented with a history of venous thrombotic 
disease and was found to be homozygous for the mutation. The variant protein dcmonslratcd reduced heparin affinity and reduced antiprolcinase 
activity in the prcscncc of cithcr unfractionatcd hcparin or the AT-binding hcparin pcntasaccharide. when compared to normal AT. A small change 
in the isoclcctric point was also idcntilied. The substituted amino acid rcsiduc of AT Budapest 3 is located near to the proposed AT heparin binding 
site, and it is suggested that rcdueed heparin affinity of the variant protein may result from substitution-induced distortion of positive charge 
gcomctry in the binding site and/or changes in its position relative to the rcsl of lhc inhibitor molecule. 
Antithrombin: Hcparin binding; Womozygous mutation: Hcrcdilary thrombosis 
1. INTRODUCTION 
AT is the main physiological inhibitor of the acti- 
vated serine proteinases ofthe coagulation system. For- 
mation of complexes between thrombin and AT is acccl- 
erated at least wo-thousand-fold in the presence of hep- 
arin and a similar enhancement is seen for inhibition of 
factors Xa and IXa (reviewed in [I]). There is evidence 
that in vivo heparin sulphate, located on the endothelial 
cell surface, fulfills the same role as extrinsic hcparin [2]. 
The mechanism by which heparin accelerates the anti- 
proteinase activity of AT is broadly understood but 
several aspects remain to be clarified. In this respect the 
identification of the heparin binding domain of the AT 
protein is of crucial importance. One approach is the 
study of naturally occurring variants with impaired 
ability to interact with this glycosaminoglycan. We re- 
port here the analysis of AT Budapest 3 and show that 
the reduced hcparin affinity of the variant is associated 
with an amino acid substitution at position 99. 
2. MATERlAlS AND METHODS 
I!. I . CNSC hi.srwy 
WC studied the presenting individual from a previously idcntilird 
kindred sqxclcd of having an AT variant with impaired hcpalin 
allinity. AT Budapest 3 [3]. The proband is the only lhmilv member 
to have had clinical thrombotic disease. Hcparin cofactor and immu- 
nological AT assays and crossed immunocleclrophoresispcrformed in 
the prcscncc of heparin demonstrated an abnormal AT protein with 
impaired hcparin binding in the plasma of the prcscnting fcmalc. with 
no trace of normal AT. Roth her parents. her two sisters and matcmal 
grandmother wcrc found to have the abnormal AT in addition to a 
normal component. 
Blood was collceted inlo cilratc anticoagulanl from the proband. 
the plasma scparatcd t’ronr lhc cells and stored al -70°C. Conlrtil 
normal plasma was oblaincd from healthy volunlecrs. AT anligcn 
Icvcls :.crp nssaycd using Bchring NorParligcn plates. The afinily of 
pla*wa AT for hcparin was measured by clution from a hcpat’in- 
Scpharosc (Phurmacia) co!umn with a NaCl gradient as dcscribcd [4]. 
The ability of unfractionatcd hcparin and the specific AT-birs” ? 
pcntasaccharidc acccleratc the antiprotcinase acuvuy 01 tbc variant 
was studied using plasma from the proband and normal individuals 
in a hcparin cofactor assay. based upon t!x anti-factlrr Xa (Coatcst. 
KabiNtrum) assay. For this. the conditions wcrc cssenlially identical 
to those suggeacd by the manul%cturcr. cxccpt the conccntfation of 
added hcparin (Lro Laboratoriw Prinecs Risborough, UK! and pen- 
tasaccharidc (a kind gill from Dr. J. Choay. Sanofichoay. Paris1 was 
varied. as indicaled. 
SDS-PAGE was carriud OUI using the Phast byslcm (Pharmacia). 
Isoelectric focusing also was carricxl out on the Phasl system. using 
premadc 4-6.5 1ET; gels. For this. plasma with cubjcct lo focusing and 
the protein was transl’ernxl (Phast Translbr. Pharmacial onto ImmO- 
blin manbrancs. incubated with anti-AT antibody (D;lkop;ltts. High 
Wyeombc, UK9 and then peroxidasc couphx! swine anti-rabbi1 1gG 
iD;lkop;ttts, Hi& Wpiornh). 
3. RESULTS 
AT assays showed a reduction in bth hcparin co- 
factor activity (Fig. 1) and AT immunological quantita- 
tion (77%; normal X0-120%). A reduction in hcparin 
afTinity was obsecxed by hcparin-Sepharosc hromatog- 
raphy. Whereas normal AT from control plasma clutcd 
from the column at 0.88 M NaCl. AT from the plasma 
of the proband was recovcrcd at 0.48 M NaCl. as a 
single peak, consistent with the prcscncc of AT protein 
with reduced hcpatin atTinity in her plasma and no nor- 
mal AT component. Both unfractionatcd hcparin and 
the AT-binding pcntasaccharidc H-IX feund to have 
diminished ability to accelerate the antiprotcinase activ- 
ity of the Budapcs~ 3 AT. when cumpartd to normal 
AT, in a plasma hsrd assay (Fig. I\. At high concqntra- 
tions ol’ the pcntasaccharic’c. however, mkmal anti- 
protcinasc activity could be induced in the Budapsst 3 
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Fig. 2. Nonreducing SDS polyacrylamide gel and isoelectric focusing 
gel. each with normal (N) AT in MI lane and AT Budapest 3 (B3) in 
Ihc right kmc. Tht major normal AT band (arrowcd) migrates with 
pI 5._%. while that 01’ AT Uudaprjt 3 larrnwcd) migr;itc> with pl 5.75. 
rZT consistent with a mutation that alters the hcparin 
binding domain. but not the reactive site of the inhibi- 
tor. AT Budapest 3 purified by hepari . Scphairosc 
chromatography showed equal mobility to normal XT 
on SDS-PAGE under nnnrcducing conditions (Fig. 2). 
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Fig. 3. DNA sequence analysis of the AT genes of the proband in the 
region of codon 99. The sequencing teraplate is amplified DNA so 
both alleles are sequenced together. A single T (arrowed) is seen in the 
first position of codon 99. instead of the normal C, indicating a ho- 
mozygous C-~T substitution. 
Isoelectric focusing revealed a shift in the isoelectric 
point of the major component of the variant AT (Fig. 
2) from 5.50 to 5.75. 
DNA sequence analysis revealed a single mutation, 
the substitution ofT  for C in the first position of codon 
99 (Fig. 3) in both AT alleles of the proband. This 
predicts the replacement of the normal eucine by phe- 
nylalanine. The proband is clearly homozygous for the 
mutation, compatible with the inheritance of a mutant 
allele from each of her parents, who as protein pheno- 
typic data had already suggested were both heterozy- 
gous for aheparin binding AT variant. The total coding 
region of the AT alleles of the proband and the flanking 
intron segments were sequenced and no further muta- 
tions were observed. Furthermore, the proband was 
homozygous for the previously described AT gene se- 
quence polymorphisms; the Budapest 3 allele was asso- 
ciated with the short length polymorphism 5" to the gene 
[8], the absence of the Pstl cutting site within exon 4 
[10], the GTA sequence within codon 295 [11] and the 
presence of the Ddel cutting site at position 60 within 
intron 5 [12]. The C--~T substitution within codon 99 
wa~ not found in 142 AT alleles from normal unrelated 
individuals, screened by allele-specific priming of the 
PCR, confirming that the change was not a sequence 
polymorphism but unique to AT Budapest 3. 
4. DISCUSSION 
We have identified the mutation L99F (.C.TC-->TTC) 
as the basis of the AT variant Budapest 3. The proband 
from the Budapest 3 kindred is homozygous for the 
mutant a!lele and has suffered recurrent venous throm- 
boembolic disease. Since the proband was also homozy- 
gous for sequence polymorphisms within the AT gent, 
it is likely that the mutant AT alleles are of  a single 
origin. This would be consistent with previous labo- 
ratory evidence that both parents were heterozygous for 
this AT variant and would suggest consanguinity within 
the family. The absence of clinical thrombotic disease 
in the parents and other family members who appear to 
be heterozygous on laboratory testing[3] is consistent 
with the previous demonstration that thrombosis n in- 
dividuab hetero~gous for heparinbinding variants is 
very uncommon [13]. 
The proband represents he fifth repo~ individual 
homozygous for an AT variant whose grin- ~y abnor- 
mality is decrea~l h~parin affinity. It is apparent that 
homozygosity for L99F has a milder phenoDlae both in 
terms of laboratory assays and clinical disease. In three 
of the other four cases the mutation was identified as 
R47C [14-16] while the molecular basis of  AT Fon- 
tainebleau [17] has not been reported. In contrast to AT 
Budapest 3, the other four cases all had minimal affinity 
for heparin and this was reflected by the absence of 
heparin cofactor activity. Whereas the quantity of AT 
Budapest 3 in the plasma of the proband was just below 
the lower limit of the normal range, plasma AT in the 
other homozygous individuals was actually raised. Clin- 
ically the proband studied here has had only venous 
thrombotic disease, while all four of the other patients 
had episodes, sometimes recurrent, ofarterial thromba- 
sis. It is tempting to suggest that the difference in clinical 
course is a reflection of the severity of impairment of 
anticoagulant activity of the variant antithrombins. 
Table i
Residues implicated in AT heparin binding 
AT residue Substitution or Equivalent Referenc~ 
modification residue of 
aj-antitqrpsin* 
17 17N, AT Rouen II! none [23] 
R24 R24C, AT Rouen IV none [24] 
P41 P41L. AT Basel HI6 [25] 
R47 R47C AT Toyama T22 [15] 
ix~, : ~, Rouen I [26] 
R4qS, AT Rouen II [19] 
W49 HNB modification N24 [27] 
L99 AT Budapest 3 H73 this report 
KI07 S-DABITC modification N81 [28] 
K l l4  TNBS modification 187 [29] 
KI25 TNBS modification E98 [291 
S-DABITC modification [2g] 
PSP modification [30] 
RI29 RI29Q, AT Geneva TI02 1311 
HPG modification i32] 
N 135 AT~ S108 [33] 
K136 S-DABITC modification QI09 [28] 
R145 HPG modification G117 [3-'2] 
*see Fig 4a alignment. HNB. hydrox)nitrobenzyk HPG (.a-hydroxy- 
phenyl)g*yo~ai; PSP, pyridoxal Y-phosphate; S-DABITC. 4-N,N-di- 
methylaminoazobenzene-4'-isothiocyano-2"-sulfonic acid; TNBS. tri- 
nitrobcnzcn¢ suIfo, lie acid. 
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The AT Budapest 3 variant demonstrates reduced 
heparin affinity by heparin-Sepharose chromatogra- 
phy, and a diminished rate of antiproteinase activity 
un-  
: fracti6nat~ heparin :0r 'the AT-binding ~ntasaecha- 
:Hde2 R~U~d hepaHn affinity and heParin cbfactor ac- 
tivity are consistent :with the iidentiiicati0n o f  a L99F 
substitution and :eu~ent cbncepis :of ihe AT heparin 
bindin~ ~:~a;~: T;'~e AT residues listed in Table 1 ap- 
pear to participate dhgctlv in heparin binding or lie in 
close proximity to the heparin binding site. These resi- 
dues were identified by studies of antithrombin genetic 
,,ariants and the glycosylation isoform, AT-]/, and 
through chemical modification experiments (rel~rences 
in Table I). Crystallographic studies of cleaved AT [18] 
and modelling studies using the structurally homolo- 
gous serpin 0h-antitrypsin [19,20] show that the residues 
implicated in AT heparin binding map to two spatially 
contiguous elements on the surface of the inhibitor mol- 
ecule. These are: (i) the amino-terminal polypeptide of 
AT, which is not present in other members of the serpin 
family, and (it) the helix D region, which contains a high 
density of positively charged amino acids in AT relative 
to other serpins. Basic residues of the AT heparin bind- 
ing site are believed to interact with negatively charged 
sulphate groups on heparin. 
Figure 4 shows the location of the AT Budapest 3
substitution i a model of the AT heparin binding site 
based in the crystal structure of the prototypical serpin 
¢x~-antitrypsin which shares a common three-dimen- 
sional template with AT [18,20]. The illustration in Fig. 
4b was generated by aligning the sequences of AT and 
~t-antistrypsin (Fig. 4a), and marking the positions of 
amino acids corresponding to AT residues implicated in 
heparin binding (Table I) onto the structure lbr post- 
complex (cleaved) 0q-antitrypsin [21]. In this model, the 
heparin binding domain is present as a region of high 
positive charge density, composed of basic residues 
from the A and D helices and probably also the amino 
,q 
Fig. 4. (A) Partial sequences of human AT and human ,g-antitrypsin, 
aligned as in Huber and Carrell [20]. Residues implicated in AT hep- 
grin binding are boxed (see Table t). (- I  indicates gaps in the aligned 
sequences, invariant and highly conserved serpin residues are under- 
lined. (^) marks residues located in alpha helices and (*) marks resi- 
dues in/S-sheets of cleaved o~-antitrypsin [21]. hX designates helix X; 
sXY, strand X in sheet Y. (B) Location orthe AT Budapesl 3mutation 
in a model of the AT heparin binding site based on the structure of 
posteomplex ~zcantitrypsin [21]. Ribbon diagram shows the helix D- 
containing surface of Brookhaven Protein Structure Database ntry 
5APt onto which the side chains for 0h-antitrypsin residues equivalent 
to those implicated in AT heparin binding (see Table i and Fig. 4a 
alignment) have t~,en drawn. Notation aaX/aaY indicates that amino 
acid X of r,~-antitt3,psin c~rresponds Io amino acid Y of AT. Location 
of the non-homologous N-terminal polypeptide of AT can be inferred 
from the disulphide bond pattern 1CB-C128, C21-C95) to extend from 
the asterisk marking the position of AT Ci28, through that marking 
C95. to that marking the amino terminal of helix A, 
terminal polypeptide. A model of the AT heparin bind- 
ing site based on the strncture of native ovalbumin 122] 
leads to the same conclusion (data not shown). 
L99, the substituted residue of AT Budapest 3. is 
located in :helix C; which li~ undem~th the heparin 
binding domain. In this location,: the L99F Substitution 
could ~urb  the ge0met~ of the positively charged 
surfa~ an~or alter its posiiion relativ6 io the rest of the 
inhibitor molecule. This could occur in several ways. 
For example, L99 is located near to N96, a glycosyla- 
tion site of AT; alteration i  the degree of glycosylation 
at this she could affect heparin interaction .v:'i its bind- 
ing site on AT through steric blockage or increased 
exposure of charged amino acids. Alternatively, the 
L99F substitution may displace the N-terminal element 
of the heparin binding domain, which is fixed to helix 
C by a disulphide bond between the nearby C95 and 
C21. Finally. substitution of L99 by a bulkier phenyla- 
ianine residue may distort interaction between helix C 
and the amino terminal end of helix D above it. Distor- 
tions produced through any of these mechanisms could 
alter the relative geometry of positive charges in the 
binding site so that heparin is bound tess efficiently, and 
might additionally interfere with protein conforma- 
tional changes proposed as the basis for AT heparin 
cofactor activity. 
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